tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Myriad Genetics (MYGN), Pfizer (PFE)

Analysts fell to the sidelines weighing in on Myriad Genetics (MYGNResearch Report), Pfizer (PFEResearch Report) and RegenXBio (RGNXResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Myriad Genetics (MYGN)

In a report issued on August 12, Puneet Souda from SVB Securities maintained a Hold rating on Myriad Genetics. The company’s shares closed last Monday at $27.88.

According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of -6.3% and a 42.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Currently, the analyst consensus on Myriad Genetics is a Hold with an average price target of $32.00, a 17.1% upside from current levels. In a report issued on August 5, Cowen & Co. also maintained a Hold rating on the stock with a $32.00 price target.

See today’s best-performing stocks on TipRanks >>

Pfizer (PFE)

In a report issued on August 12, David Risinger from SVB Securities maintained a Hold rating on Pfizer, with a price target of $105.00. The company’s shares closed last Monday at $49.75.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of 1.3% and a 42.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $61.75 average price target, implying a 23.6% upside from current levels. In a report issued on July 29, Goldman Sachs also maintained a Hold rating on the stock with a $50.00 price target.

RegenXBio (RGNX)

SVB Securities analyst Mani Foroohar maintained a Hold rating on RegenXBio on August 12. The company’s shares closed last Monday at $33.50.

According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -13.5% and a 41.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $46.60 average price target, representing a 40.2% upside. In a report issued on August 4, RBC Capital also maintained a Hold rating on the stock with a $47.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MYGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More